Kornimate/medical-research-clean huggingface dataset:
effects of electromagnetic therapy versus laser therapy on peripheral diabetic neuropathy

Conditions: Diabetes

Summary: this study are to: * evaluate effect of magnetic therapy on peripheral neuropathy in diabetic patients. * evaluate effect of laser therapy on peripheral neuropathy in diabetic patients. * compare effects of magnetic therapy with that of laser therapy on peripheral neuropathy in diabetic patients.

sixty- five male and female diabetic patients with peripheral neuropathy will be selected to participate in this study. they will be equally divided into two groups group-i: twenty five patient with diabetic peripheral neuropathy will be exposed to low intensity pulsed magnetic therapy group-ii: twenty five patients with diabetic peripheral neuropathy will be exposed for 24 treatment sessions of laser therapy group-iii 15 patient received only medical treatment

Eligibility criteria:
inclusion criteria: * all diabetic patients with peripheral neuropathy will be selected to participate in this study. * their age ranges from 35 to 65 years old. * all patients under medical control (optimal blood glucose). such as analgesic medications (e.g. opiates, anti-depressants, anticonvulsants and diabetic drugs to control blood glucose). exclusion criteria: * patients have dpn due to other causes than diabetes * ulcers in either foot * lack of blood sugar control * other nervous system impairments * visual problems * unstable medical conditions * pregnancy * metallic implants * alcohol or drug abuse.

Keywords: neuropathies laser and magnetic therapy
alcohol monitor validation

Conditions: Human Immunodeficiency Virus (HIV)

Summary: this study will validate a wrist-worn alcohol monitor (bactrack skyn) in both laboratory and real-life settings.

the overarching goal of this research program is to improve alcohol intervention and eventually related clinical outcomes (e.g., liver function) among hiv+ drinkers through biosensor-assisted intervention. research shows hiv infection can influence alcohol metabolism (i.e., higher blood alcohol levels), so it's necessary to validate the new alcohol biosensor in hiv+ drinkers rather than in general population. the primary goal of this project, as a step toward the development and evaluation of a biosensor-assisted alcohol intervention, is to validate the newly available wrist worn transdermal alcohol biosensor (bactrack skyn). the two specific aims are: (1) to assess validity and reliability of the skyn biosensor using fixed-dose lab administration of alcohol through comparison with laboratory grade breathalyzer, and (2) to validate skyn biosensor in daily life using a 2-week ecological momentary assessment (ema) to compare self-reported drinking and the skyn derived transdermal alcohol concentration (tac) readings.

Eligibility criteria:
inclusion criteria: * hiv+ consumers of alcohol; self-reported ≥ 5 days with at least 1 alcoholic drink, and ≥1days with at least 3 drinks * hiv- consumers of alcohol; self-reported ≥ 5 days with at least 1 alcoholic drink, and ≥1days with at least 3 drinks exclusion criteria: * non-drinkers * recent addiction treatment or treatment seeking * urine positive for illegal drugs except thc (not applicable to those who are only invited to do field test); * past \& current alcohol withdrawal * severe alcohol use disorder (dsm-5) * meeting criteria for current nicotine dependence (not applicable to field only participants) or current substance use disorder (excluding mild cannabis use disorder and mild/moderate alcohol use disorder) * medical conditions (other than hiv) contraindicating alcohol * pregnancy/breastfeeding in women * psychosis or other severe psychiatric conditions.

Keywords: alcohol consumption
combined chromium with letrozole versus letrozole only in induction of ovulation in patients with polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: combined letrozole with chromium versus letrozole only in induction of ovulation in polycystic ovary syndrome

randomized controlled trial

Eligibility criteria:
inclusion criteria: * female patients aged from 18 to 35 years anovulatory cycles pcos exclusion criteria: * female patients aged more than 35years male factor of infertility other factors of infertility than pcos
interest of mycophenolate for cidp weaning

Conditions: Chronic Inflammatory Demyelinating Polyradiculopathy

Summary: the main objective is to study if the mycophenolate could decrease the proportion of patients who relapse during the ivig tapering period and after the ivig withdrawal.

the secondary objectives are : * study if the mycophenolate could improve the proportion of withdrew patients. * study if the mycophenolate could improve the reduction of ivig dose or could prolong the interval between two courses of ivig compared to the baseline interval at month 12 and month 24 (= sparing treatment criteria). * study if mycophenolate could short the delay to perform the ivig withdrawal. * study if mycophenolate could improve the clinical scores (onls, r-ods mrc, incat sensory, 10 meters test) or pain score at month 12 and month 24. * study if mycophenolate could improve the quality of life at month12 and month 24. * identify clinical, biological and electrophysiological factors associated with withdrawal. * to assess the pharmacokinetics factors (area under the curve measuring the exposure to mycophenolate) and the pharmacogenetic factors (cytochrome and carrier, fcgammar) associated with withdrawal. * evaluate the tolerance of mycophenolate in this new indication.

Eligibility criteria:
inclusion criteria : * patient older than eighteen * written informed consent for study participation * definite or probable cidp according to efns/pns criteria or atypical cidp (need to meet clinical efns/pns criteria and at least 2 criteria among the efns/pns supplementary criteria) * being responder (= decrease of at least 1 point on the onls score after ivig) and dependent to ivig (= increase of at least 1 point on the onls score after ivig withdrawal or during the tapering period) * having received at least 3 courses of ivig * negative pregnancy test for women of child-bearing age exclusion criteria : * no social security benefit * pregnancy or intention to become pregnant * nursing mother * recent or active vih or hepatitis b or c , or lyme infections * monoclonal igm gammapathy with anti mag antibodies or canomad syndrome * neutropenia \< 1g/l * malignancy during the 10 years before the inclusion * patients having received mycophenolate * history of allergy to mycophenolate or placebo excipient * patients having received immunosuppressive drugs during the 3 months period before the inclusion * patients receiving : plasma exchange, magnesium hydroxide, aluminium hydroxide, cholestyramine

Keywords: chronic inflammatory demyelinating polyradiculopathy intravenous immunoglobulin (ivig) withdrawal quality of life clinical trial cost
prevalence of anemia and growth assessment in acute gastroenteritis

Conditions: Acute Gastroenteritis

Summary: 1. assessment of the growth parameters in infants admitted with acute gastroenteritis. 2. determine the prevalence of anemia in infants admitted with acute gastroenteritis.

gastroenteritis is inflammation of the stomach, small intestine, or large intestine, leading to a combination of abdominal pain, cramping, nausea, vomiting, and diarrhea. acute gastroenteritis usually lasts fewer than 14 days. worldwide, gastroenteritis affects 3 to 5 billion children each year. up to 40% of children aged less than 5 years with diarrhea are hospitalized with rotavirus. also, some microorganisms have been found predominantly in resource-constrained nations, including shigella spp, vibrio cholerae, and the protozoan infections. malnutrition, immunosuppression, young age, and an increase in the preceding diarrhea burdens are risk factors for the development of persistent diarrhea. a substantial proportion of global malnutrition is due to impaired intestinal absorptive function resulting from multiple and repeated enteric infections. these include recurrent acute infections as well as persistent infections, even those without overt liquid diarrhea. child growth is internationally recognized as the best global indicator of physical well-being in children because poor feeding practices-both in quantity and quality-and infections, or more often a combination of the two, are major factors that affect physical growth and mental development in children. the most important measurements needed for growth assessment are recumbent length or height, weight and head circumference. these fundamental anthropometric measures should be obtained and interpreted at each well child visit, and are typically sufficient for growth assessment. in this study, the prevalence of anemia and growth of infants admitted with acute gastroenteritis at assiut university children hospital will be assessed. anemia is a global public health problem, with important consequences for human health and the social and economic development of each nation. it results from single or multiple causes that act simultaneously, influencing children's health, their cognitive and physical development, and immunity, increasing the risk of infections and infant mortality.

Eligibility criteria:
inclusion criteria: * infants with acute gastroenteritis. * infants aged from 1 month and up to 2 years. exclusion criteria: * infants aged less than 1 month and more than 2 years. * infants with persistent and chronic diarrhea. * infants with acute gastroenteritis in association with chronic disease
surgeons' mental distress and risks after severe complications following radical gastrectomy

Conditions: Mental Health

Summary: surgeons experience higher levels of work stress, even under normal circumstances. many can suffer from substantial levels of mental health issues, especially when faced with severe complications. however, due to a variety of reasons, many surgeons are reluctant to disclose mental health issues or seek psychological help. gastric cancer is the fifth most common malignancy globally and accounts for the fourth leading cause of death from cancer. in china specifically, gastric cancer is a major public health issue, with some 400,000 new cases diagnosed every year. of those cases, more than 80% patients are at advanced stages when diagnosed. at present, radical gastrectomy is considered the standard approach for patients with resectable advanced gastric cancer. severe complications following radical gastrectomy ranged from 2.7% to 9.4% worldwide. in addition to delaying patients' recovery courses, severe complications also place enormous pressure on chief surgeons who performed the operations. such pressures may bring great risks of psychological distress. surgeons are also the victims when they encounter severe complications following radical gastrectomy. their mental distress should not be minimized. until now, little has been known about the effects of surgical complications on surgeons. in the current study, based on a large-scale questionnaire survey in china, the investigators aimed to investigate incidences of surgeons' mental distress following severe complications after radical gastrectomy. the investigators also aimed to identify independent risk factors which could help develop strategies to improve the mental well-being of these surgeons after such incidences.


Eligibility criteria:
inclusion criteria: * general and/or gastrointestinal surgeons who experienced severe complications after radical gastrectomy. exclusion criteria: * other conditions that do not meet the inclusion criteria.
lispro mid mixture (mm) intensive mixture therapy with progressive dose-titration of lispro low mixture (lm) or biphasic insulin aspart 30/70 (s019)

Conditions: Diabetes Mellitus, Type 2

Summary: investigation into patients with type 2 diabetes mellitus not achieving adequate glycemic control while treated with combination of premixed insulin analogue formulations twice daily and metformin will be randomly assigned to follow one of two insulin treatment strategies used in combination with metformin administration. the aim of the trial is to try to achieve optimal metabolic control and explore full therapeutic potential of the strategies, patients in both arms will follow progressive insulin dose titration algorithms for 16 weeks.


Eligibility criteria:
inclusion criteria: * have type 2 diabetes (world health organization \[who\] classification). * are at least 30 years of age and less than 75 years of age. * have been receiving hypoglycemic treatment with premixed insulin analogue (either with insulin lispro lm or biphasic insulin aspart 30/70) administered twice daily in combination with at least 1500 milligrams (mg) of metformin per day for at least 60 days immediately prior to the study. * have a hemoglobin a1c 1.2 to 1.8 times the upper limit of the normal reference range at the local laboratory at visit 1 or * have at least 6 of 9 of the postprandial blood glucose values recorded in the period between visit 1 and visit 2 exceeding 180 milligrams per 100 milliliters (mg/dl) (10.0 millimole per liter \[mmol/l\]). * have given written informed consent to participate in this study in accordance with local regulations. exclusion criteria: * are taking any other oral anti-diabetic medication (oam) not mentioned in inclusion criterion. * have a body mass index greater than 40 kilograms per meter squared (kg/m2). * have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study. * have congestive heart failure. * have an irregular sleep/wake cycle (for example, patients who sleep during the day and work during the night).

Keywords: diabetes type 2
perception of objects and natural scenes in people with vision loss (activis)

Conditions: Vision Loss

Summary: the loss of central vision causes difficulty not only in reading but also in faces recognition, and in particular in the identification of facial expression, objects or spaces. these visual deficits have been mainly studied in relation with reading, which is the main complaint of these kind of patients. however, there are not enough data regarding perception of objects and spaces in this population. then, the objectives are to study the visual-spatial abilities in individuals with vision loss, and altered cognitive processes, (2) to develop clinics tools for early detection and quantification of visual-spatial deficits and (3)to understand the capacities of normal peripheral vision in order to test the possibility of potential training for use of peripheral vision when central vision is impaired by an ophthalmic pathology.


Eligibility criteria:
inclusion criteria cases: * patients with eye disease causing loss of central or peripheral vision * french speakers * age between 18 and 90 years old * written consent * health insurance inclusion criteria controls: * sex and age matched controls (+/- 5 years) * french speakers * normal visual examination with visual acuity of min 9/10 exclusion criteria: * psychiatric disease or neurological pathologies * communication difficulties (deafness / mutism) * drug treatment altering concentration * mental deterioration with mms \<24 * alcoholism or addiction to drugs * persons under guardianship

Keywords: vision loss object recognition space recognition
cemiplimab and isa101b vaccine in adult participants with recurrent/metastatic human papillomavirus (hpv)16 cervical cancer who have experienced disease progression after first line chemotherapy

Conditions: Cervical Cancer

Summary: the primary objective of the study is to estimate the clinical benefit of cemiplimab + isa101b after progression on first line chemotherapy, as assessed by objective response rate (orr). the secondary objectives of the study are: * to characterize the safety profile of cemiplimab + isa101b * to assess preliminary efficacy of cemiplimab + isa101b as measured by duration of response (dor), progression-free survival (pfs), and overall survival (os)


Eligibility criteria:
key inclusion criteria: 1. adult patients ≥18 years of age (or the legal age of adults to consent to participate in a clinical study per country specific regulations). 2. has histologically confirmed recurrent or metastatic hpv16 positive cervical cancer as determined by an investigational hpv16 pcr assay, who have experienced disease progression after treatment with platinum containing therapy as defined in the protocol 3. patient must be determined to be positive for hpv16 genotype, as determined by a specified central reference laboratory. 4. patient must have measurable disease as defined by recist 1.1. 5. must have received prior bevacizumab and taxol unless meets pre-specified protocol criteria 6. ecog performance status of 0 or 1. 7. has adequate organ and bone marrow function as defined in the protocol. 8. anticipated life expectancy ≥20 weeks. key exclusion criteria: 1. prior treatment with an agent that blocks the pd-1/pd-l1 pathway. 2. prior treatment with other systemic immune-modulating agents as defined in the protocol 3. major surgery or radiation therapy within 14 days of first administration of study drug 4. has received treatment with an approved systemic therapy within 4 weeks of first dose of study drug, or has not yet recovered (ie, grade ≤1 or baseline) from any acute toxicities except for laboratory changes as described in the protocol 5. has another malignancy that is progressing or requires active treatment and/or history of malignancy other than cervical cancer within 3 years of date of first planned dose of study drug as defined in the protocol 6. has any condition that requires ongoing/continuous corticosteroid therapy (\>10 mg prednisone/day or anti-inflammatory equivalent) within 4 weeks prior to the first dose of study drug. 7. has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol note: other protocol-defined inclusion/ exclusion criteria apply

Keywords: hpv16 positive squamous histology recurrent metastatic adenocarcinoma/adenosquamous histology
relevance of ultrasound screening for foetal macrosomia

Conditions: Pregnancy

Summary: management of fetal macrosomia is based on a suspicion of macrosomia (no certainty before birth). this management is an artificial induction of labour for an earlier delivery and therefore a lower fetal weight gain. several studies have already shown that ultrasound performed during the third trimester of pregnancy was not a perfect tool for this screening.

the aim of the study is to describe management of women whose child is macrosomal but has not been screened g using ultrasound during the third trimester of pregnancy.

Eligibility criteria:
inclusion criteria : patients (consecutive inclusions) : women pregnant women followed in the gynaecology and obstetrics department of the chu of reims, the chg of charleville mézières or the chg of chalons en champagne. women for which the delivery is planned in the gynaecology and obstetrics department of the reims university hospital, the charleville mézières general hospital or the chalons en champagne general hospital. non-inclusion criteria women without ultrasound dating scan in the first trimester. women having a contraindication to labour or vaginal delivery women with a scarred uterus women having a history of shoulder dystocia or obstetric trauma women having a history of urinary or fecal incontinence women having a history of bad birth experience with high psychological impact women with maternal pathologies (excluding gestational diabetes) women whose fetus is breech women with twin pregnancy

Keywords: fetal macrosomia ultrasound shoulder dystocia induction of labour cesarean
horticultural practices for children

Conditions: Internet Addiction Level; Perceived Stres Level; Social Skill Level

Summary: the study was conducted with a parallel group randomized controlled experimental design to determine the effect of horticultural practices on internet addiction, social skills and stress levels in children. the children underwent horticultural practices for 6 weeks. children were given a post-test at the end of the intervention program (week 6), a first follow-up three months after the intervention and a second follow-up six months later.


Eligibility criteria:
inclusion criteria: * studying in the 6th and 7th grade of secondary school * volunteering to participate in the research * consent by the family for participation in the study exclusion criteria: - the presence of a disease against the materials to be used in horticultural practices (pollen, plant, seed and fertilizer allergy, etc.)

Keywords: horticultural practices internet addiction perceived stres social skill
nutrition for asthmatics

Conditions: Asthma

Summary: determine to what extent three distinct dietary approaches improve asthma control and lung function.

this is a crossover design pilot trial that will recruit 15 adults with asthma. participants will undergo screening and a lead-in period before being randomized to a series of three, 7-day diets with a 7+ day washout period between each diet. asthma control and lung function will be assessed at the completion of each diet. the goal of this pilot trial is to understand the effect of diet on asthma and conduct an exploratory analysis on factors that may predict the response to diet.

Eligibility criteria:
inclusion criteria: * age: 18-65 years * bmi: 18.5 - 29.99 kg/m2 * asthma diagnosed by medical specialist (confirmed in medical history) * partly controlled or uncontrolled asthma by asthma control test score ≤22 * owns a device compatible with zephyrx platform * stable asthma medication use (no change in the past 2 months). exclusion criteria: * diabetes or using diabetes medications that may lower blood glucose levels * point of care fasting blood glucose ≥126 mg/dl or triglycerides ≥400 mg/dl * current smoking or smoking history of greater than 10 pack-years * other significant respiratory or cardiac disease or the presence of clinically important comorbidities, e.g., copd, renal failure, liver disease; uncontrolled hypertension defined as systolic blood pressure ≥160 mm/hg, or diastolic blood pressure ≥100 mm/hg * pregnant or nursing women * food preferences or allergies inconsistent with study diet capabilities * noncompliance with lead-in period requirements.

Keywords: ketone diet metabolism
impact of exercise therapy on functional capacity in patients listed for liver transplantation

Conditions: Liver Cirrhosis; Liver Dysfunction

Summary: a uk prospective, single-centre feasibility study investigating the effects of exercise therapy on functional capacity in patients on the waiting list for liver transplantation. patients will receive a 12-week home prehabilitation program (daily step program; functional resistance exercise sessions; telephone health call or virtual clinic). the following will be assessed at weeks 0, 6 and 12 weeks: feasibility (recruitment, compliance, safety, patients perception), functional capacity (iswt, spbt), psychological wellbeing (hads questionnaire) and quality of life (eq-5d)

as above

Eligibility criteria:
inclusion criteria: * meet the united kingdom liver transplant criteria for listing * accepted on the liver transplant waiting list for a primary transplant * adults ≥18years who have an indication for a liver transplant * diagnosed with sarcopenia at liver transplant assessment exclusion criteria: * significant cardiovascular instability including a recent myocardial infarction, recent cerebrovascular accident and/or a recent unstable arrhythmia * unstable encephalopathy - open to interpretation by the chief investigator * patient or next of kin non-english speaking * inpatients * refusal or lacks capacity to give informed consent

Keywords: prehabilitation liver transplant functional capacity exercise